Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,048 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Clear all
Completed No phase listed Observational Accepts healthy volunteers

Modulation of Immunity by Hormonal Contraceptives

NCT02011711
View directory record Official record
Conditions
Contraception
Interventions
Not listed
Lead sponsor
Thomas L. Cherpes
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 22, 2026, 12:32 AM EDT
Active, not recruiting Phase 1 Interventional

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

NCT02403505
View directory record Official record
Conditions
Rectal Cancer
Interventions
CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Biological
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 12:32 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

HPV Vaccine Reduced Dose

NCT06799494
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injection, Lorazepam
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 12:32 AM EDT
Completed No phase listed Observational

Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load

NCT00025922
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Role of Leptin in the Neuroendocrine and Immune Response to Fasting

NCT00140231
View directory record Official record
Conditions
Fasting
Interventions
r-metHuLeptin, placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 22, 2026, 12:32 AM EDT
Completed No phase listed Observational

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

NCT01777802
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
Interventions
SBRT, IMRT, Brachytherapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

NCT01189383
View directory record Official record
Conditions
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Interventions
IL15-DC Vaccine
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

NCT00973895
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
Interventions
VRC-FLUDNA057-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 12:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With Immune Function Abnormalities

NCT00128973
View directory record Official record
Conditions
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 4 Interventional

Randomized Influenza Vaccine Evaluation of Immune Response

NCT03598439
View directory record Official record
Conditions
Influenza
Interventions
Standard IIV4, Recombinant, Cell-culture
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate Supplementation During Final Examination Stress

NCT03159273
View directory record Official record
Conditions
Airway Disease
Interventions
Beetroot Juice Group
Dietary Supplement
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 50 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 22, 2026, 12:32 AM EDT
Not listed No phase listed Observational

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

NCT03145922
View directory record Official record
Conditions
Sarcoidosis, Sarcoidosis, Pulmonary
Interventions
Observational Study
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RiteStart Personal Nutritional Dietary Study

NCT05130905
View directory record Official record
Conditions
Healthy Nutrition
Interventions
RiteStart Supplement
Dietary Supplement
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Sandy City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 22, 2026, 12:32 AM EDT
Terminated No phase listed Observational

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04852822
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Duarte, California • Orange, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

NCT02231866
View directory record Official record
Conditions
Healthy Adult Immune Responses to Vaccine
Interventions
VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 12:32 AM EDT
Recruiting No phase listed Observational

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

NCT00029445
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 12:32 AM EDT
Completed No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

NCT04794829
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01536054
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 22, 2026, 12:32 AM EDT
Not listed No phase listed Observational

Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients

NCT04465981
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
Sampling
Diagnostic Test
Lead sponsor
INanoBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 22, 2026, 12:32 AM EDT
Terminated No phase listed Observational

Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy

NCT02310594
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 22, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 22, 2026, 12:32 AM EDT